Is cholesterol the major lipoprotein risk factor in coronary heart disease? - A France-Scottish overview

Current Medical Research and Opinion

Volumn 13, Issue 10, 1997, Pages 603-616

  Fruchart, J C ^a   Packard, C J ^b  

^a INSTITUT PASTEUR DE LILLE   (France)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cholesterol; Coronary heart disease; Fibrinogen; Risk factors; Triglycerides

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

CHOLESTEROL BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; REVIEW;

EID: 0030832103     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113334     Document Type: Review

References (23)

1. Castelli, W. P., (1984). Epidemiology of coronary heart disease: the Framingham study. Am. J. Med., 76 (2A), 4-12.
2. Assmann, G., Schulte, H., von Eckardstein, A., and Huang, Y., (1996). Highly density lipoprotein cholesterol is a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 124 (Suppl), S11-S20.
3. Shepherd, J., Cobbe, S., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H., and Packard, C. J., (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl J. Med., 333, 1301-1307.
4. Scandinavian Simvastatin Survival Study Group, (1994). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
5. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., Davis, B. R., and Braunwald, E., (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl J. Med., 335, 1001-1009.
6. Hokanson J., and Austin, M. A., (1996). Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Cardiovas. Risk, 3213-219.
7. Ericsson, C. G., Hamsten, A., Nilsson, J., Grip, L., Svane, B., and de Faire, U., (1996). Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet, 347, 849-853.
8. Committee of Principal Investigators, (1978). A comparative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J., 40, 1069-1118.
9. Dorr, A. E., Gundersen, J., Schneider, J. C., Spencer, T. W., and Martin, W. B., (1978). Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J. Chron. Dis. 31, 5-14.
10. Lipid Research Clinics Program, (1988). The lipid research coronary primary prevention trial results. 1: Reduction in incidence of coronary heart disease. J. Amer. Med. Assoc., 251, 351-364.
11. Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P. Huttunen J. K., Kaitaniemi, P., Koskinen, P., and Manninen, V., (1987). The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med., 317, 1237-1245.
12. Manninen, V., Tenkanen, L., Koskinen, P., Huttunen, J. K., Manttari, M., Heinonen, O. P., and Frick, M. H., (1992). Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation, 85, 37-45.
13. Carlson, L. A., and Rosenhamer, G., (1988). Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 223, 405-418.
14. Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., and Smink, R. D., (1990). Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on surgical control of the hyperlipidemias (POSCH). N. Engl. J. Med., 323, 946-955.
15. Hahmann, H. W., Bunte, T., Hellwig, N., Hau, U., Becker, D., Dyckmans, J., Keller, H. E., and Schieffer, H. J. (1991). Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am. J. Cardiol., 67, 957-961.
16. MAAS investigators, (1994). Effect of simvastatin on coronary atheroma; the multicentre anti-atheroma study (MAAS). Lancet, 344, 633-638.
17. Pitt, B., Mancini, J., Ellis, S. G., Rosman, H. S., Park, J. S., and McGovern, M. E., (1995). Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC 1): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol., 26, 1133-1139.
18. Jukema, J. W., Bruschke, A. V., van Boven, A. J., Reiber, J. H., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J., van Rappard, F. M., and Lie, K. I., (1995). Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. REGRES. Circulation, 91, 2528-2540.
19. Farnier, M., Bonnefous, F., Debbas, N., and Irvine, A., (1994). Comparative efficacy and safety of micronised fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidaemia. Arch. Int. Med., 154, 441-449.
20. Lee, A. J., Lowe G. D. O., and Woodward, M., (1993). Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br. Heart J., 69, 338-342.
21. Tallis, G. A., (1994). Atherogenicity of triglyceride-rich lipoproteins. J. Cardiovasc. Risk, 1, 202-206.
22. Ihnken, K., Speiser, W., and Ruf, W., (1993). High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of acute myocardial infarction. Ann. Hematol., 67, 237-244.
23. Fuster, V., Badimon, L., Badimon, J. J., and Chesboro, J. H., (1992). The pathogenesis of coronary artery disease and the acute coronary syndrome. New Engl J. Med., 326, 242-244.